In 1990, more than 10 years after the discovery that the low molecular weight GTPase Ras is a major contributor to human cancer, farnesylation, a lipid posttranslational modi®cation required for the cancercausing activity of Ras, emerged as a major target for the development of novel anticancer agents. However, it took only 5 years from 1993, when the ®rst farnesyltransferase inhibitors (FTIs) were reported, to 1998 when results from the ®rst phase I clinical trials were described. This rapid progress was due to the demonstration of outstanding antitumor activity and lack of toxicity of FTIs in preclinical models. Although, many FTIs are currently in phase II and at least one is in phase III clinical trial, the mechanism of FTI antitumor activity is not known. In this review a brief summary of the development of FTIs as antitumor agents will be given. The focus of the review will be on important mechanistic and bench-to-bedside translational issues. Among the issues that will be addressed are: evidence for and against inhibition of the prenylation of Ras and RhoB proteins in the mechanism of action of FTIs; implications of the alternative prenylation of K-Ras by geranylgeranyltransferase I (when FTase is inhibited) in cancer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; eects of FTIs and GGTIs on cell cycle machinery and progression and potential mechanisms by which FTIs and GGTIs induce apoptosis in human cancer cells. A thorough discussion about bench-tobedside issues relating to hypothesis-driven clinical trials with proof-of-principle in man will also be included. This section will cover issues relating to whether the biochemical target (FTase) 
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Inhibition of prenyltransferases as a novel approach to cancer therapy
Many low molecular weight GTPases require prenylation, a lipid posttranslational modi®cation, for proper cellular localization and biological function (Casey, 1992; Reiss et al., 1990; Zhang and Casey, 1996) . Among these are the Ras superfamily proteins that are intimately involved in malignant transformation. For example, the four mammalian Ras proteins, H-, N-, K A -and K B -Ras require farnesylation in order to induce malignant transformation (Barbacid, 1986 (Barbacid, , 1987 Casey, 1992; Reiss et al., 1990; Zhang and Casey, 1996) . On the other hand, R-Ras and TC-21 that promote tumorigenesis and/or metastasis are geranylgeranylated (Zohn et al., 1998) . Furthermore, RhoA, Rac1 and cdc42 also require geranylgeranylation to promote malignant transformation and metastasis and to mediate Ras transformation (Zohn et al., 1998) . Protein farnesylation and geranylgeranylation are catalyzed by FTase and GTTase I, respectively (Zhang and Casey, 1996) . These posttranslational modi®cations result in the covalent attachment of farnesyl and geranylgeranyl groups to the cysteine thiol of proteins that end at their carboxyl termini with the consensus sequence CAAX where C is cysteine, A is aliphatic and X is any amino acid. GGTase I prefers as substrates proteins where X is leucine whereas FTase prefers X to be methionine, serine, glutamine or cysteine (Casey, 1992; Zhang and Casey, 1996) . The observation that many FTase and GGTase I substrates play a pivotal role in malignant transformation and that farnesylation and geranylgeranylation are required for their ability to promote tumorigenesis and/or metastasis, prompted many investigators to develop FTIs and GGTIs as novel anticancer drugs (Cox and Der, 1997; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000b; Sun et al., 1999a) . approach used the two substrates for FTase, the CAAX tetrapeptide and farnesyl pyrophosphate (FPP) as starting points to design FTIs. This approach was complemented by random screening of corporate chemical libraries, synthetic combinatorial libraries and/or natural products (Cox and Der, 1997; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000b; Sun et al., 1999a) .
The ®rst approach was aided by the fact that FTase recognizes and farnesylates the CAAX tetrapeptides with similar anity to the full-length Ras protein. These tetrapeptides are potent competitive inhibitors of FTase in vitro (IC 50 values ranging from 20 to 200 nM). However, because of low cellular uptake and proteolytic degradation the peptides are inactive in whole cells. To overcome these obstacles many investigators designed CAAX peptidomimetics, with fewer peptidic features but that retain high potency towards inhibiting FTase. Some of the strategies used included replacement of the central`AA' dipeptide by peptidase-resistant spacers. Another approach involved modi®cation of the peptide backbone. Further strategies incorporated structural elements of both substrates CAAX and FPP to make bisubstrate transition state analogs. Finally, FPP mimics have also been made. Many of these inhibitors, as well as some that were identi®ed from random screening are shown in Figure 1 and have been described thoroughly in other reviews, including a recent book entirely dedicated to FTase as a cancer therapy target (Sebti and Hamilton, 2000b) .
In our laboratory, we have used several strategies to design peptidomimetics of CVIM, the carboxyl terminal tetrapeptide of K B -Ras. These included a systematic replacement of the central dipeptide, the amino terminal cysteine and the carboxy terminal methionine (Lerner et al., 1995a (Lerner et al., ,b, 1997 Nigam et al., 1993; Qian, 1994; . For example, FTI-205 is a ®rst generation CVIM peptidomimetic where the dipeptide`VI' was substituted with aminomethylbenzoic acid (Nigam et al., 1993) . FTI-276 is a third generation peptidomimetic where`VI' was replaced by 2-phenyl-4-aminobenzoic acid (Lerner et al., 1995a) . FTI-2148 is a derivative of FTI-276 where the cysteine and the phenyl were replaced by an imidazole derivative and a tolyl group, respectively (Sun et al., 1999a) . Similar strategies were used to design CVLL peptidomimetics such as GGTI-298 and GGTI-2154 as GGTase I inhibitors Sun et al., 1999a) .
Biochemical properties
Most of the inhibitors shown in Figure 1 block FTase with potencies in vitro in the nanomolar to low micromolar range. Although we will be using our FTIs to illustrate these biochemical eects throughout this review, other FTIs show similar eects (Cox and Der, 1997; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000b) . Both FTI-276 and FTI-2148 are highly potent and selective for FTase (IC 50 values of 0.5 nM and 1.4 nM) over GGTase I (50 nM and 1700 nM, respectively). In whole cells, this selectivity is respected where the corresponding methylesters FTI-277 and FRI-2153 inhibit H-Ras farnesylation with IC 50 values of 100 nM and 30 nM, respectively, with no eects on Rap1A geranylgeranylation at these concentrations. GGTI-297 and GGTI-2154, on the other hand, inhibit selectively GGTase I (IC 50 values of 55 nM and 21 nM, respectively) over FTase (203 nM and 5600 nM, respectively). In whole cells, the corresponding methyl esters GGTI-298 and GGTI-2166 inhibit Rap1A processing with IC 50 values of 5 mM and 300 nM, respectively. No eects on H-Ras processing were observed at these concentrations Figure 1 Chemical structures of various FTIs (Lerner et al., 1995a; McGuire et al., 1996; Sun et al., 1999a) . (Cox and Der, 1997; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000b) . Constitutive activation of this MAP kinase pathway by a geranylgeranylated mutant of oncogenic H-Ras (CVLL) or oncogenic Raf was not aected by FTI-277 further con®rming the selectivity of these agents (Lerner et al., 1995a) . A drawback of these studies, however, is that H-Ras, not K-Ras was used; yet K-Ras is the most prevalent mutated form of Ras found in human tumors (vide intra).
K-Ras is geranylgeranylated when FTase is blocked: both FTIs and GGTIs are required for inhibition of K-Ras prenylation in human cancer cells
Initial studies with K-Ras demonstrated that inhibition of K-Ras prenylation and oncogenic signaling in NIH-3T3 cells requires high concentrations of FTIs that also inhibit GGTase I (Lerner et al., 1995a (Lerner et al., ,b, 1997 . Furthermore, K-Ras was shown to be a substrate for GGTase I in vitro (James et al., 1995) and in human cancer cells treated with FTIs, K-Ras, but not H-Ras, becomes geranylgeranylated (Rowell et al., 1997; Whyte et al., 1997) . Consistent with this, inhibition of K-Ras prenylation in several human cancer cell lines was resistant to FTI-277 and required co-treatment with FTI-277 and GGTI-298 (Lerner et al., 1997; Sun et al., 1998) . These results suggest that inhibition of the growth of human tumors that contain mutated K-Ras may require co-treatment with both FTIs and GGTIs.
FTIs inhibit human tumor growth in nude mice, increase mice life span, induce tumor regression in transgenic mice and inhibit chemical carcinogenesis Although both FTIs and GGTIs are required for inhibition of K-Ras prenylation, each alone is sucient to inhibit human tumor growth in nude mice xenografts (Sun et al., 1998) . The ability of FTIs alone to suppress tumor growth suggests that farnesylated proteins other than K-Ras play a critical role in tumor transformation and survival. Furthermore, the ability of GGTIs to inhibit tumor growth also suggests that some substrates of GGTase I are pivotal to malignant transformation. This is consistent with the tumor promoting activity of RhoA and Rac1, two substrates of GGTase I (Zohn et al., 1998) . Several laboratories have shown that FTIs, at doses of 10 ± 100 mg per Kg per day, inhibit the growth of human tumors with multiple genetic alterations including K-Ras mutations, p53 deletions or mutations and a silenced p16, a cyclindependent kinase inhibitor (Cox and Der, 1997; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000b; Sun et al., 1999a Sun et al., , 1995 . We have also shown in collaboration with Dr Ian Pollack (University of Pittsburgh) that FTIs increased the life span of nude mice implanted intracranially with the human glioblastoma U87 cell line (Bredel et al., 1998; Pollack et al., 1999) . These results suggested that FTI-276 is able to cross the blood brain barrier and was eective in blocking the growth of a tumor in its own microenvironment and result in improved mice survival.
In collaboration with Dr Ming You (Medical College of Ohio) we have also demonstrated that FTI-276 inhibits chemically-induced tumors in immunocompetent mice. This carcinogenesis/chemoprevention model uses NNK to induce lung tumors with KRas mutations in A/J mice (Lantry et al., 2000) . These results further document the outstanding antitumor ecacy of FTIs and complement the above nude mouse studies in demonstrating that FTIs are capable of suppressing the growth of tumors in their own microenvironment.
Finally, another model that has been used extensively to document that FTIs not only delay tumor growth but actually induce tumor regression is that of transgenic mice bearing oncogenes under the control of the mouse mammary tumor virus (MMTV) promoter . The ®rst model used is that of v-H-Ras transgenic mice which develop aggressive mammary and salivary tumors. In this model, treatment with FTIs induces regression of very large tumors to undetectable levels. However, even in these studies, drug removal resulted in eventual tumor regrowth. In transgenic mice that express oncogenic K B -Ras and in transgenic mice that overexpress wild type N-Ras, FTIs did not induce mammary tumor regression but exhibited potent antitumor activity by inhibiting further tumor progression Omer et al., 2000) . In transgenic mice overexpressing c-neu, FTIs inhibited neither tumor regression nor progression. Finally, FTIs induced regression in oncogenic H-Ras transgenic mice that lack p53 (v-H-Ras/p53(7/7)) as well as v-H-Ras/c-myc mice (reviewed in Gibbs et al., 2000) . The mechanism by which FTIs in these studies induced tumor regression was suggested to be apoptosis. It was found that the extent by which FTIs induce apoptosis depends on the genetic background. Those tumors with mutated HRas all underwent apoptosis and this was not dependent on wild type p53 since signi®cant apoptosis occurred in v-H-Ras/p53(7/7) tumors .
In addition to their impressive antitumor ecacy in animal models, FTIs are not toxic. For example, animals treated for over 2 months with FTI-276 (50 mpk per day) showed no weight loss or overall toxicity (Sun et al., 1995 (Sun et al., , 1998 (Sun et al., , 1999a . Similar lack of toxicity has been observed in many dierent studies (Cox and Der, 1997; Gibbs et al., 2000; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000a) . Further evidence of lack of toxicity came from our work in collaboration with Dr Richard Carthew (University of Pittsburgh) involving the eects of FTIs and GGTIs on activated Ras1-induced eye malformation in Drosophila Melanogaster (Kaumann et al., 1995) . This study demonstrated that these inhibitors when microinjected at a larvae stage of eye development, are eective at reversing the constitutively activated Ras1-induced eye malformation without aecting normal eye development (Kaumann et al., 1995) .
Combination of FTIs and GGTIs with taxol, gemcitabine, cisplatin or radiotherapy
Both nude mice and transgenic mice studies demonstrated that the eects of FTIs are reversible (Cox and Der, 1997; Gibbs et al., 2000; Gibbs and Oli, 1997; Hamilton, 1997a,b, 2000b) . This suggested that combination therapy may be bene®cial. To explore this possibility we have implanted s.c. FTI-2148-containing mini-pumps (25 mg/kg/day614 days) (in mice bearing A-549 cells s.c.) two days prior to treatment with either gemcitabine (80 mpk (i.p.) every 4th day, three times), or cisplatin (5 mpk (i.p.) every 4th day, three times). Our studies have shown that combination therapy is more ecacious than monotherapy (Sun et al., 1999a) . Similar results were obtained with taxol and FTI-2148. In all cases the eect was additive rather than synergistic. We have also demonstrated that GGTI-2154 in combination with either gemcitabine, cisplatin or taxol was more eective than monotherapy (Sun et al., 1999a) .
In collaboration with Drs Bernhard, McKenna and Muschel from the University of Pennsylvania FTI-277 was shown to sensitize H-Ras transformed ®broblasts to radiation-induced apoptosis (Bernhard et al., 1996) . More recent studies have shown that human tumors with H-Ras mutations are also radiosensitized by FTI-277. However, human tumors with K-Ras mutations required both FTI-277 and GGTI-298 (Bernhard et al., 1998) .
Lessons from mechanistic studies

Which substrate of FTase is farnesylated X?
The outstanding antitumor ecacy and lack of toxicity of FTIs suggest that a farnesylated protein or proteins are critical to tumor survival and oncogenesis. However, FTase has many substrates and to date it is not known which of these farnesylated proteins is critical. One of the most sought after questions in the FTI ®eld is: What is farnesylated X?
It all started with Ras as target X Initially the rationale behind developing FTIs as anti-cancer agents was to target the 30% of human cancers where Ras is mutated (Barbacid, 1986 (Barbacid, , 1987 . This is reasonable since all four Ras proteins, H-, N-, K A -and K B -Ras are substrates of FTase, and their farnesylation is required for their cancer-causing activity (Casey, 1992; Cox and Der, 1997; Gibbs and Oli, 1997; Reiss et al., 1990; Hamilton, 1997a,b, 2000a; Zhang and Casey, 1996) . As a consequence, in Rastransformed ®broblasts, FTIs inhibit oncogenic HRas-dependent signaling, transformation and tumor growth in nude mice (Lerner et al., 1995a; Sun et al., 1995) . However, there are several observations that argue against Ras being the critical target for FTIs, at least in some human tumors. First, in human cancer cell lines, the ability of FTIs to inhibit tumor growth does not correlate with the Ras mutation status in these cell lines (Nagasu et al., 1995; Sepp-Lorenzino et al., 1995) . Second, in H-Ras-transformed rodent ®broblasts, the kinetics of FTI-induced reversal of the transformation phenotype does not correlate with the kinetics of inhibition of Ras-farnesylation (Prendergast et al., 1994) . Third, in human cancer cells treated with FTIs, K-Ras and possibly N-Ras, but not H-Ras, become geranylgeranylated (Lerner et al., 1997; Rowell et al., 1997; Whyte et al., 1997) , yet the growth of these cancer cells in soft agar and nude mice is still inhibited (Lerner et al., 1997; Sun et al., 1998 Sun et al., , 1999a . This suggests that farnesylated proteins other than K-Ras and N-Ras are targets for FTIs. On the other hand, K-Ras and N-Ras could still be critical targets if K-Ras-GG and N-Ras-GG are antagonists of human tumor growth. Furthermore, although mutated K-Ras is the most prevalent form of Ras in human tumors, there are human cancers where H-Ras is mutated (Barbacid, 1986 (Barbacid, , 1987 , and in these cancers H-Ras, which does not get geranylgeranylated (Rowell et al., 1997; Whyte et al., 1997) , is clearly a solid candidate for target-X. There are important dierences in the function of the dierent Ras proteins. H-Ras has been shown to activate preferentially the PI3-kinase/Akt survival pathway, whereas K-Ras prefers to activate the Raf/ MEK/Erk transformation pathway (Voice et al., 1999; Yan et al., 1998) . Therefore, in human cancers that harbor wild type H-Ras, but that are dependent on the H-Ras/PI3-kinase/Akt pathway for survival, FTIs may be very eective at inducing apoptosis. Finally, inhibition of the prenylation of wild type forms of Ras may also contribute to FTI antitumor activity in human cancers with aberrant pathways upstream of Ras, such as overexpression of erbB1 and erbB2 where wild type Ras mediates malignant transformation. In conclusion, although there is some evidence arguing against, there is also evidence that argues for Ras being target X.
Inhibition of RhoB farnesylation is not a target for FTIs in human cancer cells It has been suggested that RhoB, a low molecular weight GTPase that is both farnesylated and geranylgeranylated by FTase and GGTase I, respectively, is a target for FTIs. Because of this dual prenylation, in order for RhoB to be a target, RhoB-F should promote, whereas RhoB-GG should antagonize, malignant transformation. This is a reasonable suggestion since treatment with FTIs results in inhibition of the farnesylation of RhoB-F and increased levels of RhoB-GG in cells (Lebowitz et al., 1997a) . Other evidence that supports inhibition of RhoB-F as a mediator of FTIs' mode of action are: (a) a RhoB/RhoA chimeric protein that is exclusively geranylgeranylated was shown to be growth inhibitory ; (b) the short half life of RhoB (%2 h) (Lebowitz et al., 1995; Zalcman et al., 1995) correlates better than that of Ras (%24 h) (Shih et al., 1982) in terms of the kinetics of reversal of transformation in cultured cells; and (c) a myristylated form of RhoB that is not prenylated was shown to prevent the ability of FTIs to inhibit Ras transformation (Lebowitz et al., 1995) . However, the biochemical properties of myristylated RhoB are not the same as wild type RhoB making it dicult to interpret the data. More recently, RhoB-GG was proposed to be a critical mediator of some of the eects of FTIs based on experiments using murine ®broblasts that cannot express RhoB due to homozygous deletion of the RhoB gene (Liu et al., 2000) . However, these experiments do not support inhibition of RhoB-F farnesylation as a critical step in FTIs' mechanism of antitumor activity. One possible interpretation of these results is that FTIs, by inhibiting other farnesylated proteins, cause an increase in RhoB (in both its farnesylated and geranylgeranylated forms) expression which in turn suppresses tumor growth. However, even this possible mechanism can contribute only partly to FTIs' antitumor activity since the growth of Rastransformed RhoB(7/7) murine ®broblasts in nude mice was still partially inhibited by FTIs . Furthermore, RhoB is not necessary for FTIs to inhibit anchorage-independent growth since the ability of Ras-transformed RhoB(7/7) murine cells to grow on soft agar was blocked by FTIs .
There are several key observations, in addition to those discussed above, that argue strongly against inhibition of RhoB-F farnesylation as a mediator for FTIs' mechanism of antitumor activity: (a) unlike Ras, RhoB is not found mutated in human cancers; (b) unlike its closely related family member, RhoA (Khosravi-Far et al., 1995; Qiu et al., 1995) , RhoB is not required for Ras transformation. Indeed, RhoB(7/7) murine ®broblasts are still transformed by Ras ; (c) for RhoB to be a target for an anticancer drug, it must promote cancer growth. Yet, RhoB suppresses human tumor growth in soft agar and nude mice ; in contrast to Ras, RhoA and Rac1 which promote malignant transformation (Barbacid, 1986 (Barbacid, , 1987 Zohn et al., 1998) ; (d) the proportion of RhoB-GG in cells is greater than that of RhoB-F (Adamson et al., 1992; Lebowitz et al., 1997a) questioning whether the FTIinduced changes in this ratio could explain the potent antitumor activity of FTIs and (e) the most direct evidence against RhoB-F as target X comes from cloning and biologically characterizing forms of RhoB that are either exclusively farnesylated or geranylgeranylated .
These studies demonstrated that RhoB-F is just as potent as RhoB-GG at inhibiting human tumor cell growth and IGF-1 stimulation of Akt and constitutive activation of Erk2. RhoB-F is also just as potent as RhoB-GG at inducing apoptosis and inhibiting human tumor growth in soft agar and nude mice . Thus, although there is some evidence that suggests RhoB as target X, most of it is indirect. Furthermore, there is ample evidence against inhibition of RhoB farnesylation as being critical to the mode of action of FTIs. Signi®cantly, most studies in support of RhoB as target X were performed in rodent ®broblasts transformed with H-Ras not K-Ras, whereas those that do not support this hypothesis were carried out in human cancer cells that harbor K-Ras mutations. Therefore, whether RhoB-F promotes and RhoB-GG antagonizes transformation in murine ®broblasts deserves careful examination. Furthermore, the role of RhoB in promoting H-Ras and antagonizing K-Ras transformation should also be investigated.
The HRas/PI3K/Akt/BAD survival pathway as a target for FTI-induced apoptosis It is clear from the studies described that the search for farnesylated X must continue. Our approach to identifying farnesylated X is to determine pathway X: a signaling pathway (targeted by FTIs) where farnesylated proteins are pivotal to transformation and survival of human cancers. The tumor regression induced by FTIs in transgenic mice prompted many investigators in the ®eld to evaluate the ability of FTIs to induce apoptosis. Lebowitz et al. (1997b) demonstrated that FTIs can induce apoptosis but only when cells are deprived from substratum attachment. This suggested that adhesion pathways protect cells from FTI-induced apoptosis. Suzuki et al. (1998) found that attached cells can be induced to undergo apoptosis but only when deprived of serum suggesting that growth factors in the serum rescue cells from FTI-induced apoptosis. We have found that in some human cancer cell lines, FTI-277 induces apoptosis in the presence of serum and under attached conditions (Jiang et al., 2000) . In this study, there was a correlation between the levels of the protein kinase Akt-2 and the ability of FTI-277 to induce apoptosis. Furthermore, FTI-277-induced apoptosis was rescued by a constitutively activated form of Akt-2 (Jiang et al., 2000) . These studies suggest that in human cancer cells that overexpress Akt-2, a farnesylated protein upstream of PI3-Kinase and Akt-2 mediates survival of these tumors, and that FTI-277 by inhibiting the farnesylation of such a protein induces apoptosis. Consistent with this, we have found that FTI-277 blocks growth factor and adhesion (integrin) stimulated PI3-kinase and Akt-2 activation and subsequent phosphorylation of the proapoptotic protein BAD (Jiang et al., 2000) . Thus, in human cancer cells that overexpress Akt-2, FTI-277 induces apoptosis by a mechanism that involves inhibition of the PI3-Kinase/Akt-2 pathway. This mechanism does not appear to be operational in Ras-transformed rodent ®broblasts where FTIs induce apoptosis by a mechanism independent of the PI3Kinase/Akt pathway . Thus, the ability of FTIs to induce apoptosis depends on the cell type as well as the genetic alterations of such cells.
FTIs arrest human cancer cells in prometaphase during mitosis by inhibiting bipolar spindle formation and chromosome alignment
The ability of FTIs to inhibit human cancer cell growth may also be mediated by eects on cell cycle progression. Flow cytometry experiments using a panel of human cancer cell lines demonstrated that, depending on the cell line, FTIs can either induce a G0/G1 block, G2/M accumulation or have no eect on cell cycle distribution (Vogt et al., , 1997 . Whether FTIs block in G0/G1 appears to depend on their p53 mutation status (Sepp-Lorenzino and Rosen, 1998). In human cancer cells where FTIs induce G2/M accumulation, this appears to be mediated by a prometaphase arrest (Ashar et al., 2000; Crespo et al., 2001) . Consistent with this ®nding, FTI-2153 was shown to inhibit bipolar spindle formation and chromosome alignment at the metaphase plate (Crespo et al., 2001) . Although Ashar et al. (2000) hypothesized that the centromere-associated proteins CENP-E and -F may be involved, our data (Crespo et al., 2001) and that of others (Lee et al., 2000) argue against CENP-E and -F as targets.
GGTIs induce p21waf, inhibit CDK2 and CDK4 activities, induce pRb hypophorylation and cause G1 phase arrest in human cancer cells GGTIs block all human cancer cells in the G1 phase of the cell cycle (Vogt et al., , 1997 . The biochemical mechanism by which GGTIs block cell cycle progression was consistent with their ability to block human cancer cells in the G1 phase of the cell cycle. For example, GGTI-298 induces the expression of the cyclin-dependent kinase inhibitor p21 WAF at the transcriptional levels in a p53-independent manner and this involves an Sp1/TGF-b responsive element (Adnane et al., 1998; Vogt et al., 1997) . This induction of p21waf appears to be mediated by inhibition of RhoA geranylgeranylation (Adnane et al., 1998; Vogt et al., 1997) . This is consistent with the fact that Ras was shown to activate RhoA which in turn suppresses p21 transcription (Olson et al., 1998) . We have also shown that dominant negative RhoA activates whereas activated RhoA suppresses p21waf expression in human pancreatic cell line (Panc-1) (Adnane et al., 1998) . In addition to inducing p21waf expression, GGTI-298 also induced p21 and p27 partner switching from CDK6 to CDK2 (Sun et al., 1999b) . Furthermore, GGTI-298 inhibited the activities of CDK2 and CDK4 but not CDK6 and accumulated pRb in its hypophosphorylated form (Sun et al., 1999b) .
FTIs in Clinic: lessons from bench to bedside translational studies
Results from phase I clinical trials
To date, several reports have come out describing results from phase I trials that were performed with four dierent FTIs, R115777, L-778,123, SCH66336 and BMS214662 with several chronic treatment schedules as single agents as well as in combination.
R115777 was evaluated in patients with advanced solid malignancies where it was used orally with dose escalations of up to 1300 mg BID for ®ve consecutive days every 2 weeks (Zujewski et al., 2000) . In this phase I trial, R115777 was rapidly absorbed and had a biphasic elimination with an initial half life of 5 h. Peak plasma concentrations were reached within 0.5 ± 4 h, and biologically relevant steady-state plasma concentrations achieved within 2 ± 3 days. At 1300 mg BID, the following side eects were observed: neuropathy, fatigue, nausea, vomiting, headache, anemia and hypotension. Decreased CEA levels with symptom improvements and stable disease for 5 months was observed in one patient with metastatic colorectal cancer (Zujewski et al., 2000) . R115777 was also evaluated in a 21 day BID treatment schedule (Hudes et al., 1999) . MTD was reached at 240 mg/m 2 (neutropenia and thrombocytopenia). The pharmacokinetic pro®le was very similar to the above 5-day schedule. Stable disease of over 6 months was observed in two patients. Finally, R115777 was also evaluated in a 21-day, treatment schedule where some notable responses were observed. In this trial, R115777 treatment resulted in six out of 20 refractory acute leukemia patients showing clinical activity (decreased bone marrow blasts by 50%) (Lancet et al., 2000) . At high doses of 300 and 600 mg bone marrow FTase activity and MAPKinase activation were inhibited (Lancet et al., 2000) .
L-778,123 was evaluated in a 7-day continuous i.v. (35 to 1120 mg/m 2 ) treatment schedule Soignet et al., 1999) . The dose limiting toxicities were QTc prolongation, thrombocytopenia, neutropenia, vomiting and fatigue. Steady-state plasma concentration was achieved within 3 h with a half life of 0.6 ± 3 h. Maximum inhibition of the farnesylation of the hDJ2 protein in peripheral blood mononuclear cells was observed at day 4 of the infusion.
SCH66336 was evaluated in a 7-day treatment schedule where it was given orally BID (Adjei et al., 2000) . DLT was reached at 400 mg BID with diarrhea, nausea, vomiting and fatigue. SCH66336 was absorbed slowly and its t1/2 was between 4.8 and 17.6 h. Partial response (one non-small cell lung cancer patient) lasted 9 months. Inhibition of prelamin A farnesylation was documented by immunohistochemistry in surrogate tissue (buccal mucosal cells). The recommended phase II dose was 350 mg BID. SCH66336 was also evaluated in a treatment schedule of 2 weeks every 4 weeks, BID at 25 to 300 mg (Hurwitz et al., 2000) . The toxicity pro®le was similar to the above 7-day schedule and the recommended phase II dose was 200 mg BID. Finally SCH66336 was also tried in continuous daily dosing BID where at 300 and 400 mg the following side eects were observed: myelosuppression, fatigue, vomiting and diarrhea. The recommended phase II dose was 240 mg BID. In this trial, stable disease of over 9 months was observed in two patients (Eskens et al., 1999) .
BMS-214662 was used in two treatment schedules: either single i.v. dose every 3 weeks or daily (i.v.) for ®ve consecutive days every 3 weeks. The toxicities observed were fatigue, nausea, vomiting, anorexia and ataxia. The half life was 2 ± 4 h and FTase activity inhibition was documented in peripheral blood mononuclear cells (Ryan et al., 2000) . More details about these clinical studies can be found in a recent review by Patnaik and Rowinsky (2000) .
Several FTI combinations with cytotoxic anticancer drugs have also been used in Phase I clinical trial settings. For example, R115777 (100 ± 300 mg, BID, oral) was used with gemcitabine (1000 mg/M 2 ) on days 1, 8 and 15 (every 4 weeks). A similar phase I trial with SCH66336 in combination with gemcitabine resulted in impressive long-term stable disease in 11 out of 25 patients; two partial responses and two minor responses (Hurwitz et al., 2000) . Furthermore, SCH66336 and Paclitaxel combinations also resulted in four out of 10 patients with partial responses (Khuri et al., 2000) . In other combination therapy phase I trials, L-778,123 (7 day continuous infusion) was combined with Paclitaxel (3 h infusion) on day 4 of the FTI infusion, or on day 1 prior to FTI infusion. Similarly, the FTI R115777 (200 ± 500 mg, BID, oral) was combined with 5-¯uorouracil (400 mg/M 2 i.v. bolus) and leucovorin (200 mg/M 2 /2 h) in patients with advanced colorectal and pancreatic cancers. Finally, L778,123 combination with radiotherapy also resulted in two head and neck patients with complete responses and two non-small cell lung cancer patients with partial responses (Hahn et al., 2000) . For more detail about these combination therapy trials refer to reference (Patnaik and Rowinsky, 2000) . Presently, many other combinations in phase I/II trials are ongoing and the results have yet to be reported.
Proof-of-concept in man: design of hypothesis-driven clinical trials MTD vs EBD in phase I The objectives of phase I clinical trials have traditionally been to determine safety and the maximally tolerated dose (MTD) with the ultimate goal of determining a phase II dose. The reason for basing these studies on MTD is that most anticancer agents tested to date are cytotoxic agents. As more and more rationally designed therapeutics are entering clinical trials, we must rethink our strategies for moving these agents from phase I to phase II. Antisignaling agents that were designed based on speci®c molecular targets will require, in addition to, or instead of, MTD, an optimum biological dose (OBD) or an eective biological dose (EBD) as equally important end points. These biochemical correlative studies must focus on molecular targets using a mechanistic rationale. For example, in the case of FTIs that were designed to inhibit the molecular target, FTase, dose escalations should be accompanied by measuring the eects of FTIs on inhibition of FTase, in tumor samples and/or surrogates such as peripheral blood mononuclear cells (PBMNs). If, in preclinical models, inhibition of 75% tumor FTase was sucient to block tumor growth, and if in phase I trials this level of inhibition is reached with a dose that is lower than MTD, then this EBD should be used for phase II studies. Furthermore, if with this EBD no clinical responses are seen in phase II then no phase III clinical evaluations should be pursued (see more below). If, on the other hand, MTD is reached before EBD in phase I trials then the drug should not be evaluated in phase II. These critical questions of whether the molecular target is hit and whether the drug plasma levels are sucient to eectively modulate the target at doses that are lower or equal to MTD must be addressed to avoid further costly and time-consuming advanced clinical trials. Realizing these studies cannot always be done in the tumor tissues, using PBMNs as surrogates to address these pivotal translational issues must become routine in phase I clinical trials of the new millennium.
Phase II/III issues: Are phase II trials necessary with anti-signaling molecules? A critical question that is often asked is: Are phase II clinical evaluations necessary with the new rationally designed drugs and could we just move these agents directly from phase I to phase III? This important question was recently discussed during the National Cancer Institute's Stateof-the-Science conference on non-small cell lung cancer (Washington, DC, USA, June 14 ± 15, 2000) . It was recommended that phase III studies should still require feasibility and safety data from phase II. It was felt that phase II trials will remain important as they provide more data on long-term exposure and randomized pilot studies.
How much tumor FTase inhibition is required for clinical response? All the translational issues discussed above for phase I trials must be further emphasized for phase II. Even though preclinical studies suggested that complete inhibition of FTase is not required for blocking tumor growth in nude mouse xenografts (see previous section), this must be determined in phase II clinical trials. This must be done for each tumor type as the levels required for tumor response may be tumor-dependent. If tumor FTase is inhibited at 100% but no tumor response is seen, then the molecular target is not critical to the growth, survival or transforming activity of that tumor type. Even though PBMNs are just surrogates, determining the levels of inhibition of PBMN FTase required for inhibition of tumor growth is of great value and must be routinely performed.
Inhibition of protein prenylation as a biochemical correlate Since FTase farnesylates proteins, such as Ras, that are involved in oncogenesis (Barbacid, 1986 (Barbacid, , 1987 Zohn et al., 1998) , another possible biochemical correlate to evaluate is Ras prenylation. A key question is what level of inhibition of Ras farnesylation is required for tumor response. Of course, these studies are complicated by the fact that K-Ras, the most common form of Ras found mutated in human tumors, becomes geranylgeranylated when human tumor cells are treated with FTIs. Although this alternative prenylation has not yet been shown in tumors from cancer patients, there is no reason that it will not happen in these settings. One could investigate the eects of FTIs on proteins that are not alternatively geranylgeranylated, such as H-Ras, prelamin A, lamin B and hDJ2. However, the relevance of these proteins to the growth, survival and transforming activity of human tumors is not known.
Signaling pathways as biochemical surrogates Other possible biochemical end points could be downstream eectors of farnesylated proteins known to be involved in tumor growth, survival or oncogenesis. For example, our preclinical studies identi®ed the H-Ras/PI3K/Akt-2 survival pathway as a key predictor of FTI-induced apoptosis in human cancer cells that overexpress Akt-2 (Jiang et al., 2000) . One could design a phase II clinical trial to determine the levels of inhibition of Akt-2 required for inhibition of tumor growth. Furthermore, the levels of Akt-2 in tumor biopsies could be used as a predictive parameter for whether the human tumor would respond to FTIs by inducing apoptosis. As more signaling pathways that are targeted by FTIs are discovered, these can be used, after thorough validation, as biochemical correlates.
Does Ras mutation status predict clinical response?
Although it has been shown that the ability of FTIs to inhibit growth of human cancer cell lines does not correlate with the Ras mutation status (Nagasu et al., 1995; Sepp-Lorenzino et al., 1995) , this must be evaluated in phase II clinical trials. Although, this must be done for all Ras isoforms, it is particularly important for those tumors that harbor H-Ras (Barbacid, 1986 (Barbacid, , 1987 since this isoform is more sensitive to FTIs and is not alternatively geranylgeranylated when FTase is inhibited (Rowell et al., 1997; Whyte et al., 1997) . This is an easily achievable goal for phase II trials since Ras mutation status can be routinely determined on archived samples. Rowinsky, 2000) . Some demonstrations of ecacy based on the above parameters must occur prior to engaging in large scale, costly and time-consuming randomized phase III trials. For example, if patients on FTIs show a prolongation in the time-to-tumor progression compared to known time-to-tumor progession from historical data using standard therapies, then this may justify entry to phase III clinical trials. For example, in advanced NSCLC, median time to disease progression is 4 months and median survival is 8 months after standard chemotherapy (Robinet et al., 2000) . If FTI treatment results is a statistically signi®cant increase in these parameters then a decision to move to phase III is reasonable. Another measure could be percentage of patients surviving after a certain period of time. For example, approximately 35% of advanced NSCLC patients survive after 1 year. Therefore, moving to a phase III trial would be justi®able if FTI treatment resulted in a statistically signi®cant increase in the percentage of survivors over the same time period.
Selection of clinical end points
Conclusions
FTIs entered human clinical trials about 3 years ago and one of these agents is presently in phase III clinical evaluation. Despite their outstanding antitumor ecacy and lack of toxicity in preclinical animal models, whether FTIs will be ecacious in treating human cancers still requires extensive clinical testing. One of the critical issues in this ®eld is to design clever, hypothesis-driven trials with biochemical correlates for proof-of-concept. Starting with phase I; determining eective biological doses in addition to, or instead of, maximally tolerated doses is critical. Clearly, if a molecule is designed to hit a certain molecular target such as FTase, one needs to establish whether the enzyme is inhibited (phase I) and how much inhibition was necessary for tumor growth response (phase II). It is also important to know why a tumor did or did not respond to be able to design the next set of trials with relevant questions as well as to decide whether or not to continue clinical evaluation. Furthermore, clinical investigators should include in their design a study of the link between ras mutation status and response. Similarly, as bench side research identi®es signaling pathways, such as the H-Ras/PI3K/Akt-2 survival pathway (Jiang et al., 2000) , that are critical to FTIs' activities, human tumor biopsies should be screened to determine the relevance of the pathway for predicting, for example, if FTIs will induce apoptosis. This could help with determining which patients to treat with FTIs as single agents (apoptosis, regression) or in combination therapy. Careful thought should also be given to the selection of appropriate clinical end points in FTI phase II clinical trials. Conventional objective responses used to determine if cytotoxic drugs move from phase II to phase III trials are not applicable to anti-signaling drugs such as FTIs. Consequently, unless our end points are designed carefully, we could very easily discard important agents that would bene®t cancer patients. More appropriate clinical end points for FTIs in phase II trials include time-to-tumor progression, percentage of patients that progress, median survival and quality of life. Clinical results with FTIs should be compared to established data with standard therapies for particular tumor types to determine whether FTIs bring additional bene®ts before moving to phase III. There is another clinical issue that should be discussed relating to the use of FTIs in chemopreventive settings. Although therapeutic results are awaited, it is opportune to consider the possible clinical bene®ts of using FTIs after lung and breast tumor removal to inhibit cancer recurrence after surgery.
Extensive mechanistic studies from the bench side are also required to understand the mechanism by which FTIs inhibit tumor growth and/or induce apoptosis. One critical issue that remains to be addressed is the identity of the farnesylated protein target X. Even though there is evidence that farnesylated proteins other than K-Ras, such as RhoB, may be targets, further investigations are required to settle this issue. Furthermore, recent evidence in human cancer cells strongly argues against a role for the inhibition of RhoB farnesylation in the antitumor activity mechanism of FTIs . Rather, in murine ®broblasts, an increased expression of RhoB-GG has been suggested to be important for some biological eects of FTIs . However, RhoB does not appear to be involved in FTI reversal of transformation in soft agar assays and only partly involved in FTI inhibition of tumor growth in mice . Taken together, we conclude that the search for farnesylated protein X is far from completed and must continue. Another important avenue is the further investigation of GGTIs as antitumor agents. These agents have biological activities that are desirable for novel anticancer drugs as they inhibit human tumor growth in vitro and in vivo with a mechanism that is consistent with a cell cycle arrest at the G1 phase. This includes induction of the CDK inhibitor p21waf, inhibition of CDK2 and CDK4 kinase activities and induction of hypophosphorylation of the tumor suppressor pRb (Sun et al., 1999a,b) . Further evidence for targeting GGTase I for the development of novel anticancer drugs includes not only the fact that many of its substrates, such as RhoA, Rac1, R-Ras and TC-21, mediate oncogenesis and/or metastasis (Zohn et al., 1998) , but also that K-Ras becomes a substrate for GGTase I when human cancer cells are treated with FTIs (Rowell et al., 1997; Whyte et al., 1997).
